Introduction
Neoplastic meningitis also referred to as Carcinomatous meningiosis/ Leptomeningeal metastasis is a condition characterised by widespread multifocal involvement of the brain, spine, and/or roots by a metastatic or primary brain tumour. Depending on the underlying malignancy, this condition may be termed Leptomeningeal carcinomatosis, Lymphomatous meningitis, or Leukemic meningitis.
Cerebrospinal fluid examination is the gold standard in the diagnosis of leptomeningeal metastases. Malignant cells gain access to the subarachnoid space by hematogenous dissemination (crossing the Blood-Brain, Blood-CSF barrier), direct extension from a parenchymal brain lesion or1 by tracking along the spinal or cranial nerves. Detection of malignant cells in the cerebrospinal fluid due to leptomeningeal metastasis is frequently associated with diverse neurological presentations. In several patients with a positive CSF, cytological examination strikingly provides the first documentation of a neoplasm. Spread of malignant cells into the CSF implies a limited prognosis with a median survival time of 2–6 months. The prognostic relevance of the cytological detection of malignant cells in cerebrospinal fluid remains, despite advancements in biochemical analysis and central nervous system imaging, a crucial component in the advocacy of systemic and intrathecal treatment.2
Aims and Objectives
To evaluate the role of CSF cytology in the assessment of Leptomeningeal metastases.
To study the cytomorphological features in various tumours i.e. both solid and haematological malignancies.
To subject the CSF samples to ancillary techniques like Cell Block preparation, Flow cytometry, Immunocytochemistry and Molecular tests (Mutation analysis).
Materials and Methods
Inclusion criteria
Patients of both the genders and ages ranging between 1-80 years. These included both haematological and solid malignancies.
Sample collection technique
Spinal tap (Lumbar puncture), VP shunt.
Leptomeningeal involvement was documented by the presence of malignant cells in the CSF.
The Cytocentrifuge (Cytospin) technique was employed to prepare smears for analysis. Smears were stained with May- Grunwald Giemsa and Haematoxylin & Eosin stains.
Cell blocks were prepared and studied wherever possible.
Cytocentrifuged smears were prepared and reviewed by four cytopathologists independently and were subsequently classified based on the consensus as positive or negative for malignant cells.
64 cases i.e. 22 patients with solid tumours and 42 cases of haematological malignancies with CNS involvement were studied.
Tumour types represented by these patients included:
Observations & Results
Table 2
S. No. |
Primary/ Metastatic |
Number of cases (% of positives) |
1 |
Primary CNS neoplasms |
2 (3.12%) |
2 |
Metastatic malignancies |
62 (96.8%) |
Total no. of positives |
|
64 |
Table 3
Table 4
Discussion
Significance of CSF cytology and its Clinical implications
The clinical value of an early and accurate diagnosis of metastatic tumours in CSF is high even in neurologically asymptomatic patients who are in remission from neoplasms that were formerly rapidly fatal, because the effect of treatment contributes to quality of life, control of neurological symptoms and improved overall survival.
CSF examination is a routine procedure in the work-up of Pediatric Acute leukemias (Day 0). Also, CSF cytology serves to monitor the effect of Intrathecal chemotherapy in sequential CSF samples. Intrathecal therapy with drugs like Methotrexate, liposomal Cytarabine and corticosteroids is carried out until 2 consecutive CSF cytology samples are ‘Negative for malignant cells’.
Conclusion
This case series highlights the role of cerebrospinal fluid cytology as a simple and useful method that serves as a reliable diagnostic tool in the evaluation of leptomeningeal carcinomatosis. Early diagnosis is essential to maintain the quality of life and to improve survival time with treatments including intrathecal chemotherapy, systemic chemotherapy, and radiotherapy.5 The Central Nervous System is increasingly becoming a common site for metastatic involvement as the longevity and quality of life of cancer patients is improving with the advent of newer systemic therapies.6 In addition to this, many chemotherapeutic agents fail to cross the Blood- Brain and Blood- CSF barrier, leaving the CNS/ meninges as a potential tumour hideout.7
Consequently, the early identification of secondary CNS diseases made possible by cerebrospinal fluid cytology aids in prognosis, overall survival prediction, and prompt intervention.8